Early detection of ISHD in diabetic patients and determining the type of treatment

Česká verzia

Authors: Tomáš Kovárník ¹; Kristýna Bayerová ¹; Karel Kopřiva ²
Authors place of work: II. interní klinika kardiologie angiologie 1. LF UK a VFN Praha ¹; Kardiologické oddělení Nemocnice Na Homolce, Praha ²
Published in the journal: Vnitř Lék 2016; 62(3): 210-214
Category: Reviews

Summary

Diabetes mellitus is a major risk factor for the development of ischemic heart disease. Its prevalence in diabetic patients is reported to range broadly between 10–55 %. It is necessary to actively search for the presence of myocardial ischemia in patients with diabetes, since waiting for the development of symptoms is associated with the finding of already advanced coronary atherosclerosis in these patients, with less satisfactory outcomes of coronary interventions and surgery. Results of the BARDOT study seem to indicate that the appropriate tool for stratification of the risk of cardiac events in diabetics could be stress myocardial scintigraphy. This test is successful in detecting the presence of myocardial ischemia, assessing its size and location and identifying whether reversible ischemia is involved. Such data is very important with regard to choosing the right treatment strategy. We often find advanced coronary atherosclerosis in diabetic patients for which surgical treatment is more appropriate. Nonetheless in the era of modern stents also the patients with diabetes can be treated with intervention. All the influenceable risk factors for ischemic heart disease should be consistently treated by intervention in each diabetic patient, who should be given optimum pharmacotherapy. This involves medication with a proven impact on the patient prognosis, influencing the progression of coronary atherosclerosis and mitigation of myocardial ischemia..

Key words:
diabetes mellitus – ischemic heart disease – myocardial ischemia

Zdroje

1. Gowani SA, Morales DC, Ahlberg A et al. Do diabetic patients incur same cardiovascular risk as non-diabetic patients with CAD? A large population study following SPECT-MPI. J Am Coll Cardiol. 2012; 59(13s1): E1160-E1160. Dostupné z DOI:http://dx.doi.org/10.1016/S0735–1097(12)61161–9.

2. Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339(4): 229–234.

3. Zellweger MJ, Pfisterer ME. Silent coronary artery disease in patients with diabetes mellitus. Swiss Med Wkly 2001; 131(29–30): 427–432.

4. Rutter MK, Wahid ST, McComb JM et al. Significance of silent ischemia and microalbuminuria in predicting coronary events in asymptomatic patients with type 2 diabetes. J Am Coll Cardiol 2002; 40(1): 56–61.

5. Zhang L, Li H, Zhang S et al. Silent myocardial ischemia detected by single photon emission computed tomography (SPECT) and risk of cardiac events among asymptomatic patients with type 2 diabetes: a meta-analysis of prospective studies. J Diabetes Complications 2014; 28(3): 413–418.

6. Hammoud T, Tanguay JF, Bourassa MG. Management of Coronary Artery Disease: Therapeutic Options in Patients With Diabetes. J Am Coll Cardiol 2000; 36(2): 355–365.

7. Kannel W. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J 1985; 110(5): 1100–1107.

8. Meisinger C, Heier M, von Scheidt W et al. Gender-specific short and long-term mortality in diabetic versus nondiabetic patients with incident acute myocardial infarction in the reperfusion era (the MONICA/KORA myocardial infarction registry). Am J Cardiol 2010; 106(12): 1680–1684.

9. Lima E, Hueb W, Gersh B et al. Impact of chronic kidney disease on long-term outcomes in type 2 diabetic patients with coronary artery disease on surgical, angioplasty, or medical treatment. Ann Thorac Surg 2016: pii: S0003–4975(15)01707–5. Dostupné z DOI: http://dx.doi.org/10.1016/j.athoracsur.2015.10.036.

10. Rydén L, Grant PJ, Anker SD et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34(39): 3035–3087.

11. Mellbin L, Anselmino M, Ryden L. Diabetes, prediabetes and cardiovascular risk. Eur J Cradiovasc Prev Rehabil 2010; 17(Suppl 1): S9-S14.

12. Zellweger MJ, Maraun M, Osterhues HH et al. Progression to Overt or Silent CAD in Asymptomatic Patients With Diabetes Mellitus at High Coronary Risk. J Am Coll Cardiol Img 2014; 7(10): 1001–1010.

13. Prasad A, Rihal C, Holmes DR Jr. The COURAGE trial in perspective. Catheter Cardiovasc Interv 2008; 72(1): 54–59.

14. McCullough PA, Fazel P, Choi JW. Screening, Diagnosis, and Management of CAD in Asymptomatic Diabetic Patients. JACC Cardiovasc Imaging 2014; 7(10): 1011–1012.

15. Wong ND, Hui G. Angina Prevalence and Characteristics in Coronary Artery Disease Patients with and without Diabetes. J Am Coll Cardiol 2014; 63: A1538. Dostupné z DOI: http://dx.doi.org/10.1016/S0735–1097(14)61541–2.

16. Simonsen J, Johansen A, Gerke O et al. Outcome with invasive versus medical treatment of stable coronary artery disease: influence of perfusion defect size, ischaemia, and ejection fraction. Eurointervention 2016; 11(10): 1118–1124.

17. Weintraub WS, Stein B, Kosinski A et al. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. J Am Coll Cardiol 1998; 31(1): 10–19.

18. Windecker S, Kolh P, Alfonso F et al. 2014 EACTS Guidelines on myocardial revascularization. Eurointervention 2015; 10(9): 1024–1094.

19. Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372(25): 2387–2397.

20. Murphy S, Cannon Ch, Blazing M et al. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome. J Am Coll Cardiol 2016; 67(4): 353–361.

21. Hoe E, Hegele R. Lipid management in diabetes with a focus on emerging therapies. Can J Diabetes 2015; 39(Suppl 5): S183-S190. Dostupné z DOI: http://dx.doi.org/10.1016/j.jcjd.2015.09.012.

22. Yoon JW, Cho BJ, Park HS et al. Differential effects of trimetazidine on vascular smooth muscle cell and endothelial cell in response to carotid artery balloon injury in diabetic rats. Int J Cardiol 2013; 167(1): 126–133.